TaiLong Capital is a professional equity investment management institution founded in 2021 that focuses on biomedicine, innovative medical devices, CXO services, and the broader healthcare sector. The firm participates in sizeable financing rounds for emerging life-science companies, exemplified by its co-lead role in C Ray Therapeutics’ Series A+ round exceeding US$100 million.
Focus Areas
Notable Investments
